HR Execs on the Move

Hanon-McKendry

www.hanon-mckendry.com

 
Hanon McKendry is a national brand-consulting firm that excels at helping corporate and nonprofit clients shift perceptions beyond what their brand offers to what their brand means. Nearly 80 percent of the firm's annual revenues are derived from major
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

Ivera Group

As an independent forensic consulting and accounting firm we understand the needs of our clients. Your experience with the Ivera Group will be professional and timely. As our client, you will receive timely updates, status reports, and relevant informa...

Citizens For A Scenic Florida

Citizens For A Scenic Florida is a Jacksonville, FL-based company in the Business Services sector.

Yunker Industries Inc.

Yunker Industries Inc. is one of the leading providers in Business Services. It is based in Lake Geneva, WI. To find more information about Yunker Industries Inc., please visit www.yunker.com.

One Call Concepts Locating Services

One Call Concepts Locating Services is a Hanover, MD-based company in the Business Services sector.

enGene

At enGene, we are at the vanguard of a new era in genetic medicine: Our novel Dually Derivatized Oligochitosan® (DDX) gene delivery platform is designed to enable localized delivery of multiple gene cargos, including RNA and DNA, directly to mucosal tissues and other organs — potentially overcoming the limitations of viral-based gene therapies and advancing gene therapy beyond rare genetic diseases into the mainstream of clinical practice. Our breakthrough Dually Derivatized Oligochitosan® (DDX) platform opens possibilities for streamlining the use of genetic medicines in the treatment of serious diseases, especially diseases afflicting mucosal tissues. Our lead product candidate, EG-70 (detalimogene voraplasmid), is a non-viral immunotherapy in development to treat non-muscle invasive bladder cancer (NMIBC), a disease with a significant patient burden, high clinical needs, and massive healthcare system economic impact. Based on its preliminary efficacy and safety profile and ease of administration by urologists, EG-70, which is currently in a pivotal trial, can potentially benefit patients across a wide variety of clinical settings. As enGeneers, we are boldly focused on patients needs. We are a team of passionate experts with extensive experience in drug development and commercialization across oncology, respiratory, and several other therapeutic areas. Nasdaq: ENGN